Clinical trialNCT06126276RecruitingPhase 2Interventional

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

SponsorNational Cancer Institute (NCI)Enrollment70Malignant Female Reproductive System NeoplasmMalignant Solid NeoplasmRecurrent Malignant Female Reproductive System NeoplasmRecurrent Malignant Solid Neoplasm

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-express a specific biomarker called HER2.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Haider S Mahdi
NRG Oncology
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

189 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Puerto Rico

Centro Comprensivo de Cancer de Upr
San Juan, Puerto Rico
Luis J. Santos Reyes
Recruiting

United States

University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
Rebecca C. Arend
Recruiting
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States
Ahmed Abdalla
Recruiting
Alaska Women'S Cancer Care
Anchorage, Alaska, United States
Dan S. Zuckerman
Recruiting
Uc San Diego Health System - Encinitas
Encinitas, California, United States
Peter Vu
Recruiting
Uc San Diego Moores Cancer Center
La Jolla, California, United States
Peter Vu
Recruiting
Cedars-Sinai Medical Center
Los Angeles, California, United States
Omid Hamid
Recruiting
the Angeles Clinic and Research Institute - West Los Angeles Office
Los Angeles, California, United States
Omid Hamid
Recruiting
Uc San Diego Medical Center - Hillcrest
San Diego, California, United States
Peter Vu
Recruiting
Um Sylvester Comprehensive Cancer Center at Aventura
Aventura, Florida, United States
Matthew P. Schlumbrecht
Recruiting
Um Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, United States
Matthew P. Schlumbrecht
Recruiting
Um Sylvester Comprehensive Cancer Center at Coral Springs
Coral Springs, Florida, United States
Matthew P. Schlumbrecht
Recruiting
Um Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, United States
Matthew P. Schlumbrecht
Recruiting
Um Sylvester Comprehensive Cancer Center at Kendall
Miami, Florida, United States
Matthew P. Schlumbrecht
Recruiting
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, United States
Matthew P. Schlumbrecht
Recruiting
University of Miami Sylvester Comprehensive Cancer Center at Sole Mia
North Miami, Florida, United States
Matthew P. Schlumbrecht
Recruiting
Um Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida, United States
Matthew P. Schlumbrecht
Recruiting
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, United States
Tareq Al baghdadi
Recruiting
Saint Luke'S Cancer Institute - Boise
Boise, Idaho, United States
Dan S. Zuckerman
Recruiting
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho, United States
Tareq Al baghdadi
Recruiting
Kootenai Health - Coeur D'Alene
Coeur d'Alene, Idaho, United States
John M. Schallenkamp
Recruiting
Saint Luke'S Cancer Institute - Fruitland
Fruitland, Idaho, United States
Dan S. Zuckerman
Recruiting
Saint Luke'S Cancer Institute - Meridian
Meridian, Idaho, United States
Dan S. Zuckerman
Recruiting
Saint Alphonsus Cancer Care Center-Nampa
Nampa, Idaho, United States
Tareq Al baghdadi
Recruiting
Saint Luke'S Cancer Institute - Nampa
Nampa, Idaho, United States
Dan S. Zuckerman
Recruiting
Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho, United States
John M. Schallenkamp
Recruiting
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, Idaho, United States
John M. Schallenkamp
Recruiting
Sih Cancer Institute
Carterville, Illinois, United States
Bryan A. Faller
Recruiting
John H Stroger Jr Hospital of Cook County
Chicago, Illinois, United States
Suspended
University of Illinois
Chicago, Illinois, United States
Ryan Nguyen
Recruiting
Carle at the Riverfront
Danville, Illinois, United States
Maria T. Grosse-Perdekamp
Recruiting
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, United States
Bryan A. Faller
Recruiting
Decatur Memorial Hospital
Decatur, Illinois, United States
Bryan A. Faller
Recruiting
Carle Physician Group-Effingham
Effingham, Illinois, United States
Maria T. Grosse-Perdekamp
Recruiting
Crossroads Cancer Center
Effingham, Illinois, United States
Bryan A. Faller
Recruiting
Northshore University Healthsystem-Evanston Hospital
Evanston, Illinois, United States
Mary T. Jenkins Vogel
Recruiting
Northshore University Healthsystem-Glenbrook Hospital
Glenview, Illinois, United States
Mary T. Jenkins Vogel
Recruiting
Northshore University Healthsystem-Highland Park Hospital
Highland Park, Illinois, United States
Mary T. Jenkins Vogel
Recruiting
Carle Physician Group-Mattoon/charleston
Mattoon, Illinois, United States
Maria T. Grosse-Perdekamp
Recruiting
Carle Bromenn Medical Center
Normal, Illinois, United States
Maria T. Grosse-Perdekamp
Recruiting

149 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Neratinib →Palbociclib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 7 May 2024
Primary completion: 20 Feb 2027
Completion: 20 Feb 2027
Last update posted: 18 Aug 2026
Registered enrollment: 70
Registry id: NCT06126276

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.